A comprehensive view of Eisai Co. Ltd.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

European Medicines Agency delays decision on Biogen and Eisai's Alzheimer's drug lecanemab due to procedural implications from an EU court ruling; the delay is unrelated to the marketing authorization application submitted for lecanemab

Eisai obtains marketing authorization from Japan's Ministry of Health for injectable form of antiepileptic drug Fycompa; the new formulation provides an alternative therapy for patients unable to take the drug orally.

China approves Eisai's Leqembi injectable to treat minor dementia and cognitive dysfunction triggered by Alzheimer’s; China also approves Gilead's Descovy tablet for pre-exposure prophylaxis to lower the risk of HIV infection

Eisai and Biogen's Alzheimer's treatment, Leqembi, gets approval from Japan's health ministry, making Japan the second country after the US to permit its use; the drug helps reduce the progression of mild cognitive impairment and mild dementia

Merck, Eisai report immunotherapy Keytruda and the cancer drug Lenvima combined therapy fails in lung cancer trials

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count